Five years after Tercica Inc. first acquired rights to Genentech Inc.'s insulin-like growth factor-1 (IGF-1) - for which it gained approval as Increlex in 2005 for short stature in children with primary IGF-1 deficiency - the two companies expanded their collaboration to develop combination IGF-1 and growth hormone products for idiopathic short stature and adult growth hormone deficiency.(BioWorld Today)